Clinical trial
Risk of Ovarian Cancer in Patients With a Pelvic Mass
NCT00315692 · Fujirebio Diagnostics, Inc., Industry · Completed
Key facts
| NCT number | NCT00315692 |
|---|---|
| Title | Risk of Ovarian Cancer in Patients With a Pelvic Mass |
| Official title | Evaluation of a Multiple Biomarker Assay to Estimate the Risk of Ovarian Cancer in Patients Presenting With a Pelvic Mass. |
| Lead sponsor | Fujirebio Diagnostics, Inc., Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Ovarian Cancer |
| Intervention type | Device |
| Interventions | Biomarker Assay (CA125 and HE4) |
| Enrollment | 566 |
| Start date | Dec 1, 2005 |
| Completion | Feb 1, 2007 |
| First posted | Apr 19, 2006 |
| Last update posted | Nov 8, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: